Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADC189 PK/PD and Safety in Hepatic Impairment
NCT06485401Phase 1Completed
- Sponsor
- Jiaxing AnDiCon Biotech
- Start
- Mar 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of deunoxavir marboxil in influenza, Influenza A (IAV) and influenza B (4 arms), sponsored by Jiaxing AnDiCon Biotech. Primary endpoints: Maximum Plasma Concentration at 15 days and Area Under the Curve to the Last Quantifiable Concentration at 15 days. Started Mar 2024; status: completed.
02
Drugs
deunoxavir marboxil
03
Conditions
influenzaInfluenza A (IAV)influenza B
Beyond the preview
Go deeper on NCT06485401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06485401.